Clik here to view.
Should You Own Pfizer Stock?
With shares of Pfizer (NYSE:PFE) trading around $28.72, is PFE an OUTPERFORM, WAIT AND SEE or STAY AWAY? Let’s analyze the stock with the relevant sections of our CHEAT SHEET investing framework: T =...
View ArticleClik here to view.
Buying Opportunity in OncoSec Medical as Catalysts Approach
Earlier this morning, OncoSec Medical (ONCS.PK) announced its 2014 strategic update. The update provided a list of some of the upcoming events/catalysts that investors could expect. It appeared to...
View ArticleClik here to view.
2 Biotech Stocks in Play: Celsion and Chelsea
This has been another exciting week in the world of biotechnology. Several stocks are attracting investor attention, but not all for the best reasons. This article will focus on the developments at...
View ArticleClik here to view.
Ignore the Drama: Here’s Why Galena Is a Good Buy
Let me start off immediately by saying that I hold no position in Galena Pharmaceuticals (NASDAQ:GALE) and have no plans to invest in the name. I just don’t have the stomach for the volatility. I tell...
View ArticleClik here to view.
2 Healthcare Stocks on the Move: Pfizer & Tristar Wellness
Investors often wonder what it takes to hit a homerun investment. That’s a difficult question to answer because there are lots of variables that go into determining which stocks will generate the...
View ArticleClik here to view.
NeoStem: A Potential Blockbuster for Investors
Shares of NeoStem, Inc. (NASDAQ:NBS) have been very good to investors over the last nine months, gaining 40 percent based on the close this past week. A leader in the stem cell sector, NBS is beginning...
View ArticleClik here to view.
InterMune Surges on Positive Lung Drug Data
With the biotechnology industry continuing to demonstrate outstanding returns, investors may want to take a close look at a promising biotechnology company that recently announced positive Phase 3...
View ArticleClik here to view.
ANI Pharmaceuticals Continues Big Run
Investors have seen the biotechnology momentum continue during Wednesday’s trading session with several biotechnology stocks producing significant gains. While secondary offerings can often be seen in...
View ArticleClik here to view.
Why Big Pharma May Not Be Cashing in on Medical Marijuana
Source: Thinkstock Prohibition against marijuana seems to be soon nearing an end, partially motivated by Colorado’s tax windfall since its passage of Amendment 64, reporting over $3.5 million in...
View Article
